Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. - Wikidata - awgldk - TriplyDB

Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma.

Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma.

http://www.wikidata.org/entity/Q34246444

about

New advances in targeted gastric cancer treatment Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma Mechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapy Systemic therapy of hepatocellular carcinoma: current status and future perspectives Implications of biomarkers in human hepatocellular carcinoma pathogenesis and therapy Current systemic treatment of hepatocellular carcinoma: A review of the literature Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma Hepatocellular carcinoma: Where there is unmet need Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib.A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma.Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies Oncolytic immunotherapy using recombinant vaccinia virus GLV-1h68 kills sorafenib-resistant hepatocellular carcinoma efficiently.A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling.Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges.Evaluating the role of treatment-related toxicities in the challenges facing targeted therapies for advanced hepatocellular carcinoma.Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib.Hepatitis C virus-related hepatocellular carcinoma: An insight into molecular mechanisms and therapeutic strategies Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma.Akt and mTORC1 have different roles during liver tumorigenesis in mice.Antiangiogenic therapies for advanced hepatocellular carcinoma.Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours.Targeting the tumor microenvironment: from understanding pathways to effective clinical trials.Clinical trials in hepatocellular carcinoma: an update.The changing landscape of hepatocellular carcinoma: etiology, genetics, and therapy Brivanib: a review of development.Pathways and targets in hepatocellular carcinoma.New agents on the horizon in hepatocellular carcinoma.Targeted therapies in the treatment of advanced hepatocellular carcinoma Systemic therapies in hepatocellular carcinoma: present and future.Molecular targeted therapy for hepatocellular carcinoma: current and future.Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety.Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use.Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy.Hepatocellular carcinoma review: current treatment, and evidence-based medicine.Advances in managing hepatocellular carcinoma.

P2860

Q26738548-F0D213D4-9D34-48AE-834F-1693DD861F21 Q26766689-F9DECB42-25B9-43C0-BC42-9C62D3F60E04 Q26797535-3A30CBB5-8214-444D-9B60-CCFBB7F64E11 Q26798462-794DE511-734D-48F4-A073-9DA26635EBB4 Q26865844-A222A04A-9883-4691-ABAA-D96D2576B1A1 Q27005850-B89DABC3-555B-4309-856A-579673A25650 Q27026036-2BEACD52-7553-4BB0-9726-FF5AEEE96896 Q28075305-BBF5AA08-E2A1-42BF-A49B-B9C7958234F5 Q28084046-2E1DD8CB-7047-4E5F-B26B-7FF9118201FC Q33411190-029E4D40-83A9-4442-9EF6-D2A3274E7F18 Q33419633-DB576AD0-72D6-4A67-B6CC-5DEFAF5F184E Q33648955-E8242C79-091E-4484-A069-8FE654583EB1 Q33895113-A2702DBE-A66B-472E-81C3-576289E20A46 Q34438331-68BDB507-E619-42DE-BB2A-15F8BE8D1092 Q34781699-44B1845D-B0F4-4A53-824D-2DE686BE745B Q35141906-67EBC470-8291-4841-BA58-9C5E6E7C175A Q35501246-76E12CD4-04CB-4DA8-8A5C-A7A223298B0A Q35739362-03E65AC9-9CE2-4261-AC92-CAA002A387EF Q35759606-8AF3D31F-B0CD-4C86-A36C-0BD21547F48D Q35911679-C09C5EE2-A319-43E2-967A-25097AC67816 Q36561567-5084085B-44D5-46EA-9FAB-66823242760A Q36598514-6D56A6A8-2C64-430A-B4B2-68A72CEF29B4 Q36788158-6516D28A-335C-4D40-8351-B71E6D368553 Q36804518-EBB70877-D7BC-4111-A218-B527F9ABE8C2 Q37049104-8B9E8687-AB96-49DC-83CD-F6ADDF2D4AA7 Q37175085-C7484C1D-DA9E-4D75-A358-6A3FE3087927 Q37274132-94C13B5B-8226-413B-AA8F-38F07651C50C Q37435638-C54B5A0F-ACF3-4CAF-A3A3-FD8F0B4957D0 Q37606028-B143518C-CF13-4A3E-B110-D1EF993F01E8 Q38048883-BDF90A1D-5993-4012-9889-04E659E5181B Q38062022-916C8A05-6F79-406E-AA48-09EB65C6D07E Q38074429-D474B228-E164-4F1B-A50D-6260A79055BC Q38114062-3E6A0B66-C62E-4D33-B14C-7235D9BD1401 Q38150875-050B932A-FEEC-495F-914D-727FC3DF008C Q38151670-A3C50597-4E0D-46DC-9870-654B9B952059 Q38160838-91851372-686B-494C-9ED1-B589EFF5B777 Q38166329-922C2F69-41DB-4335-8CE3-59D727E1654E Q38184582-9C28E234-0DA1-473D-AD4E-953387E64208 Q38207012-AA9AB825-C7E9-4022-8738-BC4C615635FA Q38210345-B4A89BDC-B005-471D-8572-8C0379BEA96B

P2860

Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma.

http://www.wikidata.org/entity/Q34246444

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Phase II, open-label study of ...... nced hepatocellular carcinoma.

@ast

Phase II, open-label study of ...... nced hepatocellular carcinoma.

@en

Phase II, open-label study of ...... nced hepatocellular carcinoma.

@nl

type

label

Phase II, open-label study of ...... nced hepatocellular carcinoma.

@ast

Phase II, open-label study of ...... nced hepatocellular carcinoma.

@en

Phase II, open-label study of ...... nced hepatocellular carcinoma.

@nl

prefLabel

Phase II, open-label study of ...... nced hepatocellular carcinoma.

@ast

Phase II, open-label study of ...... nced hepatocellular carcinoma.

@en

Phase II, open-label study of ...... nced hepatocellular carcinoma.

@nl

P1433

Q34246444-B9E86BB8-9E0F-4EC1-A743-2B1FA2B4CD2C

P1476

Q34246444-C0361D51-D495-4E55-9FB8-5D88F2D60E81

P2093

Q34246444-35CF6343-5637-4F8D-82D0-0E021757EFF1

Q34246444-3988FF68-7B3E-4F79-9DD5-888B282725D2

Q34246444-3E9A18E3-81D1-4B27-A569-EAAB99C3C3E2

Q34246444-5438A5E3-A2A7-44E3-9818-6C3C71C8659B

Q34246444-659A46EC-A16B-41C8-93DF-01789E1101A1

Q34246444-68D3BB4D-0038-48FF-97AA-04BF0128C7C5

Q34246444-886D0F54-C8CC-491D-8F13-BBF72B25E46F

Q34246444-8CDCB024-D7BE-41E5-AE59-BDAC27BC73B5

Q34246444-F5DC7D7C-B014-4B5A-B342-9349282AD40A

P304

Q34246444-20D34178-9A7A-4240-AB79-EBDE952A86D3

P31

Q34246444-7D1F7008-8A45-4B02-A4E0-52392D5EECA0

P356

Q34246444-BD2C35D4-66D2-40B6-B80D-536FDB7EF3BF

P407

Q34246444-0381068E-E03E-4730-B159-3EB5FFFA79B9

P433

Q34246444-F455DD86-7D1C-4150-98F5-07B48D48556A

P478

Q34246444-5B71D1C1-2B61-4FC4-AE39-489BE14DB12E

P577

Q34246444-3344238D-F251-4C44-B7B1-808FF41FC0C5

P698

Q34246444-D3F26870-1D10-4445-9737-1BF010392AD3

P921

Q34246444-F6FB8AC0-C3CE-435D-9D99-4B3BAC07B4F8

P356

1078-0432.CCR-11-1991

P1433

Clinical Cancer Research

P1476

Phase II, open-label study of ...... nced hepatocellular carcinoma.

@en

P2093

Blase N Polite

http://www.w3.org/2001/XMLSchema#string

Christine Baudelet

http://www.w3.org/2001/XMLSchema#string

Demetrios Manekas

http://www.w3.org/2001/XMLSchema#string

Ho Yeong Lim

http://www.w3.org/2001/XMLSchema#string

Ian Walters

http://www.w3.org/2001/XMLSchema#string

Joong-Won Park

http://www.w3.org/2001/XMLSchema#string

Mary Mulcahy

http://www.w3.org/2001/XMLSchema#string

Richard S Finn

http://www.w3.org/2001/XMLSchema#string

Yoon-Koo Kang

http://www.w3.org/2001/XMLSchema#string

P304

2090-2098

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-11-1991

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2012-01-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22238246

http://www.w3.org/2001/XMLSchema#string

P921